Victor Golmer
Morgan Stanley downgraded Novo Nordisk to underweight from equal-weight saying it sees slowing growth of its lucrative GLP-1 franchise, which includes the weight loss med Wegovy and the type 2 diabetes drug Ozempic.
The investment bank cut its price target